Download PDF
Thromb Haemost 2008; 100(01): 160-162
DOI: 10.1160/TH08-05-0275
Letters to the Editor
Schattauer GmbH

Heparin is procoagulant in the absence of antithrombin

Stephanie A. Smith
1   Department of Internal Medicine
,
James H. Morrissey
2   Department of Biochemistry, College of Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA
› Author Affiliations
Further Information

Publication History

Received 01 May 2008

Accepted after minor revision 16 May 2008

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Tollefsen DM, Zhang L. Heparin and Vascular Proteoglycans. In: Hemostasis and Thrombosis. 5th ed. Lippincott Williams and Wilkins; 2006: 271-283.
    Google Scholar
  • 2 Fonseca RJ, Mourao PA. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Melo FR, Mourao PA. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Lindahl U. Heparan sulfate-protein interactions--a concept for drug design?. Thromb Haemost 2007; 98: 109-115.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Marcum JA, Atha DH, Fritze LM. et al. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261: 7507-7517.
    PubMedGoogle Scholar
  • 6 Kojima T, Leone CW, Marchildon GA. et al. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992; 267: 4859-4869.
    PubMedGoogle Scholar
  • 7 Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008 in press
    PubMedGoogle Scholar
  • 8 Liu T, Scallan CD, Broze Jr. GJ. et al. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Mutch NJ, Johnson KW, Morrissey JH. Non-anticoagulant sulfated polysaccharides enhance thrombin generation by accelerating factor V activation. J Thromb Haemost 2007; 05 (Suppl. 02) O-M-094.
    PubMedGoogle Scholar
  • 10 Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 1999; 68: 89-125.
    CrossrefPubMedGoogle Scholar
  • 11 Smith SA, Mutch NJ, Baskar D. et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
    CrossrefPubMedGoogle Scholar
  • 12 Mast AE, Broze Jr GJ. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996; 87: 1845-1850.
    PubMedGoogle Scholar
  • 13 Fareed J, Hoppensteadt D, Schultz C. et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 2004; 10: 983-999.
    PubMedGoogle Scholar